[Special Stock] Paksel Bio Shows Significant Results in Advanced Liver Cancer Treatment Research...16% Increase

[Asia Economy Reporter Kwon Jae-hee] On the morning of the 8th, the stock price of Vaxcell Bio is soaring.

As of 9:22 AM on the day, Vaxcell Bio is trading at 43,100 KRW on the KOSDAQ market, up 16.02% compared to the previous trading day. During the session, it rose as much as 18.17% before giving up some of the gains.

Vaxcell Bio is a company specializing in the development of anticancer immunotherapy. The stock price is believed to have risen following the announcement of preliminary research results on the progressive liver cancer treatment Vax-NK·HCC at the American Association for the Study of Liver Diseases (AASLD), the world's largest conference in the field of liver diseases. At this AASLD, Vaxcell Bio presented an e-poster containing preliminary research results showing an ORR (Objective Response Rate) of 66.7% and a DCR (Disease Control Rate) of 100%, reaffirming its excellent cell therapy technology.

Vax-NK/HCC is an autologous anticancer immune cell therapy currently undergoing clinical trials by Vaxcell Bio. It targets progressive liver cancer, which has the poorest prognosis among liver cancers, and is currently in a Phase 2a clinical trial involving a total of 20 patients.

In this preliminary research, Vaxcell Bio showed an objective response rate, which is the sum of complete and partial responses, of 66.7%, and a disease control rate including stable lesions of 100%. This is a groundbreaking figure observed in clinical trials targeting progressive liver cancer with a poor prognosis.

This content was produced with the assistance of AI translation services.